[{"indications": "Indications\u00a0\n(From Tiagabine: British National Formulary)\nTiagabine", "name": "TIAGABINE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "4 Central nervous system", "4.8 Antiepileptic drugs", "4.8.1 Control of the epilepsies", "Tiagabine"], "cautions": "Cautions\u00a0avoid in acute porphyria (section 9.8.2); avoid abrupt withdrawal; interactions: Appendix 1 (tiagabine)Driving\u00a0May impair performance of\r\nskilled tasks (e.g. driving)", "side-effects": "Side-effects\u00a0 diarrhoea; dizziness, tiredness, nervousness,\r\ntremor, impaired concentration, emotional lability, speech impairment; rarely confusion, depression, drowsiness, psychosis, non-convulsive\r\nstatus epilepticus, bruising, and visual disturbances; suicidal ideation;\r\nleucopenia also reported ", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/106094.htm", "doses": ["Adjunctive therapy, adult and child over 12 years, initially\r\n5\u201310\u00a0mg daily in 1\u20132 divided doses, increased in steps of 5\u201310\u00a0mg\r\ndaily at weekly intervals; usual maintenance dose with enzyme-inducing\r\ndrugs, 30\u201345\u00a0mg daily in 2\u20133 divided doses; initial maintenance\r\ndose without enzyme-inducing drugs, 15\u201330\u00a0mg daily\r\nin 2\u20133 divided doses"], "pregnancy": "Pregnancy\u00a0see Pregnancy"}]